Benzyllactobionamides as inhibitors of smooth muscle cell proliferation

A pharmaceutical composition which comprises a compound of formula I having the structure

• wherein
• R1, R2, R3, R4, R5, R6, R7, and R8 are each, independently, acyl of 2-7 carbon atoms, haloacyl of 2-7 carbon atoms, nitroacyl of 2-7 carbon atoms, cyanoacyl of 2-7 carbon atoms, trifluoromethylacyl of 3-8 carbon atoms, or —SO3H;
• R9 is hydrogen, CN, NO2, halo, CF3, alkyl of 1-6 carbon atoms, or alkoxy of 1-6 carbon atoms;
• R10 is hydrogen, —NO2, —NHR11, —NHR13, —N(R13)2, —NCH3R13, —NHCO2alkyl, wherein the alkyl moiety contains 1-6 carbon atoms, alkylsulfonamide of 1 to 4 carbon atoms,
• Z is O or S;
• R11 is an α-amino acid in which the α carboxyl group forms an amide with the nitrogen of R10, wherein if said amino acid is glutamic acid or aspartic acid, the non-α carboxylic acid is an alkyl ester in which the alkyl moiety contains from 1-6 carbon atoms;
• R12 is hydrogen, CN, NO2, halo, CF3, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, or acyl of 2-7 carbon atoms;
• R13 is hydrogen, acyl of 2-7 carbon atoms, haloacyl of 2-7 carbon atoms, nitroacyl of 2-7 carbon atoms, cyanoacyl of 2-7 carbon atoms, or trifluoromethylacyl of 3-8 carbon atoms;
• or a pharmaceutically acceptable salt thereof, and a pharmaceutical carrier.